12-9-04



Express Mail No. EV529782965ŲŚ

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Soumitra S. Ghosh et al.

Application No.

10/741,823

Filed

December 19, 2003

For

LIGANDS OF ADENINE NUCLEOTIDE TRANSLOCASE (ANT)

AND COMPOSITIONS AND METHODS RELATED THERETO

Examiner

Hector M. Reyes

Art Unit

1625

Docket No.

660088.467

Date

December 7, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT

## Commissioner for Patents:

In response to the Restriction Requirement mailed October 25, 2004, please extend the period of time for response one (1) month, to expire on December 25, 2004. Enclosed are a Petition for an Extension of Time and the requisite fee.

The Examiner has entered a six-way Restriction Requirement: namely, Group I claims 1-9 in part, drawn to heterocyclic compounds, pharmaceutical acceptable salts thereof, stereoisomers thereof and multiple prodrugs thereof, and pharmaceutical compositions comprising the same; Group II - claims 1-9 in part, drawn to non-heterocyclic compounds, pharmaceutical acceptable salts thereof, stereoisomers thereof and multiple prodrugs thereof, and pharmaceutical compositions comprising the same; Group III - claims 10-11 in part, drawn to multiple methods of treating medical conditions or diseases using pharmaceutical compositions comprising heterocyclic compounds or derivatives thereof; Group IV - claims 10-11 in part, drawn to multiple methods of treating medical conditions or diseases using pharmaceutical compositions comprising non-heterocyclic compounds or derivatives thereof; Group V - claims 10-11 in part, drawn to multiple methods of preventing medical conditions or diseases using

Response to Restriction Requirement mailed October 25, 2004

pharmaceutical compositions comprising heterocyclic compounds or derivatives thereof; and Group VI - claims 10-11 in part, drawn to multiple methods of preventing medical conditions or diseases using pharmaceutical compositions comprising non-heterocyclic compounds or derivatives thereof.

Applicants hereby elect, without traverse, the Group I claims for examination at this time. In addition, for purpose of initial examination only, Applicants hereby elect the species of compound 5-6 (see Table 5, page 35), having the following structure:

In view of the above remarks, consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,

Soumitra S. Ghosh et al.

Seed Intellectual Property Law Group PLLC

Emily W. Wagner

Registration No. 50,922

EWW:cw Enclosure:

Postcard

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

527609